AVEO Pharmaceuticals Inc. (AVEO)’s Financial Results Comparing With BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Both AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) are each other?s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AVEO Pharmaceuticals Inc. 4.01M 23.05 23.65M -0.20 0.00
BioSpecifics Technologies Corp. 29.81M 16.53 16.51M 2.40 29.63

Demonstrates AVEO Pharmaceuticals Inc. and BioSpecifics Technologies Corp. earnings per share, top-line revenue and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of AVEO Pharmaceuticals Inc. and BioSpecifics Technologies Corp.

Net Margins Return on Equity Return on Assets
AVEO Pharmaceuticals Inc. -589.78% 48.1% -69.9%
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%

Risk & Volatility

AVEO Pharmaceuticals Inc. has a beta of 1.13 and its 13.00% more volatile than Standard & Poor’s 500. Competitively, BioSpecifics Technologies Corp.?s 29.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.29 beta.

Liquidity

AVEO Pharmaceuticals Inc. has a Current Ratio of 1.1 and a Quick Ratio of 1.1. Competitively, BioSpecifics Technologies Corp.’s Current Ratio is 48.4 and has 48.4 Quick Ratio. BioSpecifics Technologies Corp.’s better ability to pay short and long-term obligations than AVEO Pharmaceuticals Inc.

Analyst Recommendations

In next table is given AVEO Pharmaceuticals Inc. and BioSpecifics Technologies Corp.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AVEO Pharmaceuticals Inc. 0 2 2 2.50
BioSpecifics Technologies Corp. 0 0 0 0.00

AVEO Pharmaceuticals Inc.?s upside potential currently stands at 247.71% and an $2 average price target.

Insider & Institutional Ownership

Institutional investors owned 41.9% of AVEO Pharmaceuticals Inc. shares and 61.3% of BioSpecifics Technologies Corp. shares. Insiders owned 0.3% of AVEO Pharmaceuticals Inc. shares. Comparatively, BioSpecifics Technologies Corp. has 2.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVEO Pharmaceuticals Inc. -15.19% -19.85% -72.92% -80.67% -80.4% -64.96%
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%

For the past year AVEO Pharmaceuticals Inc. had bearish trend while BioSpecifics Technologies Corp. had bullish trend.

Summary

BioSpecifics Technologies Corp. beats AVEO Pharmaceuticals Inc. on 9 of the 12 factors.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.